Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to FENIC Pharmaceuticals' fourth quarter and four-year 2025 earnings and corporate update conference call. At this time, all participants are on a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now I'd like to turn the conference over to FENIC's Chief Financial Officer, Robert Andrade. Thank you, Operator. and good morning, everyone. Thank you for joining us today. We are pleased to host Phenix Pharmaceuticals' fourth quarter and full year 2025 earnings conference call, during which we will review our financial results as well as provide a general business update. Towards the end of the call, we will conduct a Q&A session hosted by myself, starting with frequent questions that the company receives from investors. followed by our traditional open Q&A session. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Medical Officer, Dr. Pierre Sayad. Pierre is an accomplished industry executive with proven success leading global medical teams and oncology launches at companies such as Onyx Pharmaceuticals Keriopharm Therapeutics, Oncopeptides, and BTI Biopharma. Dr. Syed is a graduate of the School of Medicine of Loma Linda University, as well as a Harvard Business School alum. Since joining Fennec in the fourth quarter of 2024, Pierre has been instrumental in advancing our medical strategy and clinical evidence strategy. expanding engagement with leading institutions and key opinion leaders, and strengthening the independent data foundation supporting PEDMARC. Later in the call, Pierre will speak t...